GlassScriptPhysician profile
Bryce Hunter Gilman
NPI 1730261785
$1,402.95
in general payments reported to CMS, 2019-2025
28 companies · $364 in 2025
The $364 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2020: $182 · 2021: $104 · 2022: $97.21 · 2023: $259 · 2024: $208 · 2025: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $832.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $831.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $190.59 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $187.60 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $129.32 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Medtronic, INC. | $71.45 | 2021-2023 | Intellis Adaptivestim |
| Supernus Pharmaceuticals, INC. | $69.68 | 2021-2023 | Qelbree |
| Lilly USA, LLC | $67.72 | 2020-2025 | Mounjaro, Emgality |
| Amgen INC. | $64.06 | 2020-2022 | |
| Abbvie INC. | $63.23 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.99 | 2020-2025 | Trintellix |
| Allergan, INC. | $60.89 | 2019-2020 | |
| Pfizer INC. | $48.16 | 2022-2025 | |
| Abbott Laboratories | $43.34 | 2024-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $32.36 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.95 | 2023-2025 | Jardiance |
| Exact Sciences Corporation | $30.94 | 2025 | The Cologuard Plus Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $30.77 | 2019 | |
| Stryker Corporation | $23.46 | 2019 | |
| Glaxosmithkline, LLC. | $23.32 | 2020 | |
| Boston Scientific Corporation | $22.49 | 2020 | |
| Medtronic USA, INC. | $20.39 | 2019 | |
| Antares Pharma, INC. | $18.83 | 2019 | |
| Merck Sharp & Dohme LLC | $17.61 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $17.56 | 2024 | Rexulti |
| Grifols USA, LLC | $17.02 | 2023 | Prolastin-C Liquid |
| Phathom Pharmaceuticals, INC. | $16.85 | 2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $15.98 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.44 | 2019 | |
| Sanofi-Aventis U.S. LLC | $10.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryce Gilman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.